Tideglusib + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Arrhythmogenic Cardiomyopathy
Conditions
Arrhythmogenic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy
Trial Timeline
Mar 21, 2025 → Jul 1, 2027
NCT ID
NCT06174220About Tideglusib + Placebo
Tideglusib + Placebo is a phase 2 stage product being developed by AMO Pharma for Arrhythmogenic Cardiomyopathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06174220. Target conditions include Arrhythmogenic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06174220 | Phase 2 | Recruiting |
| NCT03692312 | Phase 2/3 | Completed |